Terry Flotte, MD, discusses the early days and possible future of gene therapy, the use of AAV to deliver GT to targeted sites in the body, and his inspiration behind becoming a physician, scientist, and medical school dean. He spoke one-on-one with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the sixth episode of Giants of Gene Therapy!

Dr. Flotte is the Provost, Dean, and Celia and Isaac Haidak Professor at UMass Chan Medical School, with faculty appointments in the Department of Pediatrics and the Horae Gene Therapy Center. He is also a practicing pediatric pulmonologist and a prolific researcher who has authored more than 280 papers and been the principal investigator of multiple clinical gene therapy trials. Dr. Flotte is the editor-in-chief of his field’s oldest journal family, Human Gene Therapy.

In 1995, Dr. Flotte was the principal investigator for the first human use of AAV vectors, in a trial in cystic fibrosis patients. He’s currently investigating the use of gene therapy for genetic diseases that affect children, including alpha-1 antitrypsin (AAT) deficiency and lysosomal storage diseases.

Dr. Flotte has been an ASGCT member since the Society’s founding. He’s served on the board and committees, and spoken at the ASGCT Annual Meeting and other events.  

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Terry Flotte, MD, discusses the early days and possible future of gene therapy, the use of AAV to deliver GT to targeted sites in the body, and his inspiration behind becoming a physician, scientist, and medical school dean. He spoke one-on-one with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the sixth episode of Giants of Gene Therapy!
Dr. Flotte is the Provost, Dean, and Celia and Isaac Haidak Professor at UMass Chan Medical School, with faculty appointments in the Department of Pediatrics and the Horae Gene Therapy Center. He is also a practicing pediatric pulmonologist and a prolific researcher who has authored more than 280 papers and been the principal investigator of multiple clinical gene therapy trials. Dr. Flotte is the editor-in-chief of his field’s oldest journal family, Human Gene Therapy.
In 1995, Dr. Flotte was the principal investigator for the first human use of AAV vectors, in a trial in cystic fibrosis patients. He’s currently investigating the use of gene therapy for genetic diseases that affect children, including alpha-1 antitrypsin (AAT) deficiency and lysosomal storage diseases.
Dr. Flotte has been an ASGCT member since the Society’s founding. He’s served on the board and committees, and spoken at the <a href="https://annualmeeting.asgct.org/">ASGCT Annual Meeting</a> and other events.  
Music by: Steven O'Brien <a href="https://protect-us.mimecast.com/s/jcayCv2rxWtyKRVTQLe7p">https://www.steven-obrien.net/</a>
"Making Progress"
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/ibdECwpvyXUR92rIq1jwO">https://creativecommons.org/licenses/by/4.0/</a>)

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

Advertisement